June 01, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Abemaciclib may be new standard for ‘challenging’ sarcoma subtype
CHICAGO — Abemaciclib significantly prolonged PFS compared with placebo for patients with advanced dedifferentiated liposarcoma, according to findings presented during ASCO Annual Meeting’s plenary session.Results of the randomized phase 3 SARC041 trial — the first-ever positive phase 3 trial in dedifferentiated sarcoma — showed a trend toward longer OS with the agent,
1,442 words~7 min read
